Undisclosed mAbXcite Conjugates

About Innate Biotherapeutics

Innate Biotherapeutics is a private, pre-clinical stage biotech leveraging a unique platform called mAbXcite, which conjugates beta-1,6-glucan to tumor-targeting antibodies. This approach aims to recruit and activate innate immune cells like neutrophils at the tumor site, initiating a cascade that primes a durable adaptive T-cell response, potentially treating a wide range of 'cold' tumors. The company is seeking strategic partnerships to advance its pipeline, which is positioned to work both as a monotherapy and in combination with established checkpoint inhibitors.

Therapeutic Areas